SCHEMBL132772

SCHEMBL132772

[c]1ccc2cccc3c2c1CC3

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 4/20 0.42
LMNA P02545 2/20 0.42
CYP3A4 P08684 3/20 0.40
TSHR P16473 2/20 0.40
ALDH1A1 P00352 6/20 0.38
HPGD P15428 5/20 0.38
KDM4E B2RXH2 4/20 0.38
MEN1 O00255 1/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
KMT2A Q03164 1/20 0.38
CYP11B1 P15538 1/20 0.34
CYP11B2 P19099 1/20 0.34
CYP1A2 P05177 2/20 0.33
CYP1A1 P04798 1/20 0.33
CYP1B1 Q16678 1/20 0.33
TYMS P04818 1/20 0.32
CYP2C19 P33261 1/20 0.32
PARP1 P09874 1/20 0.31
SCN2A Q99250 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22635716 0.89 TSHR (0.38) HSD17B10LMNACYP3A4TSHRALDH1A1
Acenaphthene SCHEMBL9017 0.75 TSHR (0.57) HSD17B10LMNACYP3A4TSHRALDH1A1
Acenaphthene SCHEMBL29386207 0.75 TSHR (0.57) HSD17B10LMNACYP3A4TSHRALDH1A1
Acenaphthene SCHEMBL1162573 0.75 TSHR (0.57) HSD17B10LMNACYP3A4TSHRALDH1A1
Acenaphthene SCHEMBL28028969 0.75 TSHR (0.57) HSD17B10LMNACYP3A4TSHRALDH1A1
Acenaphthene SCHEMBL3416108 0.75 TSHR (0.57) HSD17B10LMNACYP3A4TSHRALDH1A1
Acenaphthene SCHEMBL598252 0.75 TSHR (0.57) HSD17B10LMNACYP3A4TSHRALDH1A1
SCHEMBL29706425 0.73 TSHR (0.70) HSD17B10LMNACYP3A4TSHRALDH1A1
SCHEMBL154911 0.73 TSHR (0.70) HSD17B10LMNACYP3A4TSHRALDH1A1
Acenaphthene SCHEMBL29586283 0.73 TSHR (0.55) HSD17B10LMNACYP3A4TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4379833-A1 NEGATIVE ELECTRODE, LITHIUM ION SECONDARY BATTERY, AND MANUFACTURING METHOD FOR LITHIUM ION SECONDARY BATTERY SHIN-ETSU CHEMICAL CO., LTD. (JP) 2024-06-05 EP disclosed
CN-118043298-A (Hetero) aryl-substituted bisphenol compound and thermoplastic resin 罗伊特化学仪器制造公司 2024-05-14 CN disclosed
CN-117940399-A Heteroaryl or aryl substituted bisphenol compounds and thermoplastic resins 三菱瓦斯化学株式会社 2024-04-26 CN disclosed
CN-111094223-B binaphthyl compounds 罗伊特化学仪器制造公司 2023-10-27 CN disclosed
CN-116348558-A Inkjet ink for forming an image on a substrate, inkjet printing process and ink set, and aqueous pigment dispersion for forming an inkjet ink 西康制造有限公司 2023-06-27 CN disclosed
WO-2023008032-A1 NEGATIVE ELECTRODE, LITHIUM ION SECONDARY BATTERY, AND MANUFACTURING METHOD FOR LITHIUM ION SECONDARY BATTERY 信越化学工業株式会社 2023-02-02 WO disclosed
CN-115103675-A Compounds for the treatment and prevention of central nervous system disorders 阿巴克西斯治疗公司 2022-09-23 CN disclosed
CN-109863155-B Polycyclic aromatic compound, material for organic element, organic electroluminescent element, display device, and lighting device 学校法人关西学院 2022-09-13 CN disclosed
CN-110049990-B Polycyclic aromatic amino compound, material for organic element, organic electroluminescent element, display device, and lighting device 学校法人关西学院 2022-09-13 CN disclosed
CN-114773249-A Compounds, pharmaceutical compositions and methods for treating inflammatory diseases 艾匹克治疗公司 2022-07-22 CN disclosed
EP-1510210-A1 IMMUNITY-RELATED PROTEIN KINASE INHIBITORS Institute of Medicinal Molecular Design, Inc. (JP) 2005-03-02 EP disclosed
EP-1510207-A1 THERAPEUTIC DRUG FOR DIABETES Institute of Medicinal Molecular Design, Inc. (JP) 2005-03-02 EP disclosed
US-20040259877-A1 Inhibitors against the production and release of inflammatory cytokines INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2004-12-23 US disclosed
CN-1489458-A Inflammatory cytokine production dissociation inhibitor ��ʽ����ҽҩ��������о��� 2004-04-14 CN disclosed
EP-1352650-A1 INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES Institute of Medicinal Molecular Design, Inc. (JP) 2003-10-15 EP disclosed
US-5489709-A REACTING MONO-SUBSTITUTEED CYANAMIDE WITH A SECONDARY AMINE CAMBRIDGE NEUROSCIENCE, INC. 1996-02-06 US disclosed
EP-0634997-A4 PREPARATION OF SUBSTITUTED GUANIDINES. CAMBRIDGE NEUROSCIENCE RES (US) 1995-04-26 EP disclosed
EP-0634997-A1 PREPARATION OF SUBSTITUTED GUANIDINES CAMBRIDGE NEUROSCIENCE RESEARCH, INC. (US) 1995-01-25 EP disclosed
US-5298657-A From a cyanamide and an amine, Lewis acid catalyst CAMBRIDGE NEUROSCIENCE INC. (US) 1994-03-29 US disclosed
WO-1993019042-A1 PREPARATION OF SUBSTITUTED GUANIDINES CAMBRIDGE NEUROSCIENCE, INC. (US) 1993-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259877-A1 Inhibitors against the production and release of inflammatory cytokines NFKBIA, IL1B, IKBKB HSD17B10 704/4885LMNA 2842/4885CYP3A4 1988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.